January 24, 2017 5:00 PM ET


Company Overview of Interface Biologics, Inc.

Company Overview

Interface Biologics, Inc. develops transformative biomedical polymer technology to improve the safety and effectiveness of implantable medical devices. The company’s technology focuses on anti-thrombogenic additives and programmable combination drug delivery devices. It provides Endexo technology for blood contacting medical devices that address thrombosis problems; Epidel anti-infective polymers that allow for pharmaceuticals to be integrated directly into medical devices; and Kinesyx bioactive surface pacifying oligomers. The company was founded in 2001 and is based in Toronto, Canada.

MaRS Centre

South Tower

101 College Street

Suite 300

Toronto, ON M5G 1L7


Founded in 2001





Key Executives for Interface Biologics, Inc.

Chief Executive Officer, President and Director
Age: 55
Founder, Chief Scientific Officer, Director and Member of The Medical & Scientific Advisory Board
Vice President of Finance
Vice President of Operations
Vice President of Business Development
Compensation as of Fiscal Year 2016.

Interface Biologics, Inc. Key Developments

Interface Biologics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

Interface Biologics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

Interface Biologics, Inc. Presents at Bloom Burton & Co Healthcare Investor Conference 2016, May-02-2016 04:00 PM

Interface Biologics, Inc. Presents at Bloom Burton & Co Healthcare Investor Conference 2016, May-02-2016 04:00 PM. Venue: Sheraton Centre Toronto Hotel, Toronto, Ontario, Canada.

Interface Biologics Inc. Announces Extension of Licensing Agreement with Fresenius Medical Care

Interface Biologics Inc. announced that Fresenius Medical Care has extended their exclusive licensing agreement for use of Endexo technology in chronic dialysis systems to cover the acute dialysis market (including CRRT). Endexo is a self-locating fluoro-oligomeric additive that results in a passive surface that reduces platelet adhesion and activation, protein adsorption and thrombus formation in medical devices, thereby potentially reducing the use of drugs such as heparin. As an additive, Endexo(TM) has significant manufacturing advantages over other anti-thrombogenic coating or impregnation technologies and does not change the mechanical or functional properties of the underlying medical device.

Similar Private Companies By Industry

Company Name Region
2007262 Ontario, Inc. Americas
2056273 Ontario, Inc. Americas
AB BioPharma Inc. Americas
AbCelex Technologies Inc. Americas
AbCellera Biologics Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Interface Biologics, Inc., please visit www.interfacebiologics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.